Incidence and risk factors of acute kidney injury in patients with malignant tumors: a systematic review and meta-analysis.
Acute kidney injury
Intensive care
Meta-analysis
Risk factors
Systematic review
Tumor
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
received:
17
06
2023
accepted:
23
10
2023
medline:
27
11
2023
pubmed:
18
11
2023
entrez:
18
11
2023
Statut:
epublish
Résumé
There are significant differences in the incidence and risk factors of tumor patients, and there is no relevant statistical data. Therefore, this study aims to clarify the incidence and risk factors of acute kidney injury (AKI) in malignant tumor patients and compare critically ill patients with non-critically ill patients. Relevant literature on the occurrence of AKI in malignant tumors was retrieved from databases. Two authors independently screened and evaluated the eligibility and quality of the literature and extracted the data. The Stata 12.0 software was used for meta-analysis. A total of 3922 articles were initially retrieved, and 24 articles were finally included, 8 of which were about critically ill malignant tumor patients, and 16 were about malignant tumor patients. Among the 4107 patients included in the 8 studies on critically ill malignant tumors, 1932 developed AKI, with an incidence rate of 52% (95%CI 34-70%, I2 = 99%). The risk factors for AKI in critically ill malignant tumor patients were sepsis and hypovolemia, which were different from those in non-critically ill patients. Among the 292,874 patients included in the 16 studies on malignant tumors, 51,211 developed AKI, and the combined incidence rate was 24% (95%CI 17-30%, I2 = 100%). The risk factors for AKI in critical malignant tumor patients were sepsis and hypovolemia. This meta-analysis shows that the incidence of AKI in critically ill malignant tumor patients is consistent with that in other critically ill patients, and independent risk factors are sepsis and hypovolemia. The incidence of AKI in malignant tumor patients is higher than that in other patients, and tumor is a risk factor for AKI. This study has been registered in INPLASY (INPLASY202320079),Registered February 18,2023.
Sections du résumé
BACKGROUND
BACKGROUND
There are significant differences in the incidence and risk factors of tumor patients, and there is no relevant statistical data. Therefore, this study aims to clarify the incidence and risk factors of acute kidney injury (AKI) in malignant tumor patients and compare critically ill patients with non-critically ill patients.
METHODS
METHODS
Relevant literature on the occurrence of AKI in malignant tumors was retrieved from databases. Two authors independently screened and evaluated the eligibility and quality of the literature and extracted the data. The Stata 12.0 software was used for meta-analysis.
RESULTS
RESULTS
A total of 3922 articles were initially retrieved, and 24 articles were finally included, 8 of which were about critically ill malignant tumor patients, and 16 were about malignant tumor patients. Among the 4107 patients included in the 8 studies on critically ill malignant tumors, 1932 developed AKI, with an incidence rate of 52% (95%CI 34-70%, I2 = 99%). The risk factors for AKI in critically ill malignant tumor patients were sepsis and hypovolemia, which were different from those in non-critically ill patients. Among the 292,874 patients included in the 16 studies on malignant tumors, 51,211 developed AKI, and the combined incidence rate was 24% (95%CI 17-30%, I2 = 100%). The risk factors for AKI in critical malignant tumor patients were sepsis and hypovolemia.
CONCLUSION
CONCLUSIONS
This meta-analysis shows that the incidence of AKI in critically ill malignant tumor patients is consistent with that in other critically ill patients, and independent risk factors are sepsis and hypovolemia. The incidence of AKI in malignant tumor patients is higher than that in other patients, and tumor is a risk factor for AKI. This study has been registered in INPLASY (INPLASY202320079),Registered February 18,2023.
Identifiants
pubmed: 37978466
doi: 10.1186/s12885-023-11561-3
pii: 10.1186/s12885-023-11561-3
pmc: PMC10656870
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1123Informations de copyright
© 2023. The Author(s).
Références
Lancet. 2015 Jun 27;385(9987):2616-43
pubmed: 25777661
Rev Bras Ter Intensiva. 2010 Sep;22(3):236-44
pubmed: 25302429
Nephrol Dial Transplant. 2015 Dec;30(12):2006-13
pubmed: 26597921
Intensive Care Med. 2015 Aug;41(8):1411-23
pubmed: 26162677
Int J Nephrol. 2022 Jan 12;2022:2972275
pubmed: 35070452
Cancer. 2010 Sep 1;116(17):4063-8
pubmed: 20564156
Ann Palliat Med. 2021 Feb;10(2):2158-2166
pubmed: 33725771
Clin J Am Soc Nephrol. 2013 Sep;8(9):1482-93
pubmed: 23744003
Int J Cancer. 2019 Jun 1;144(11):2644-2650
pubmed: 30426496
Lancet. 2012 Aug 25;380(9843):756-66
pubmed: 22617274
Nephrol Dial Transplant. 2018 Nov 1;33(11):1997-2005
pubmed: 29579262
Biomed Res Int. 2016;2016:6805169
pubmed: 27803928
Aging Dis. 2022 Jul 11;13(4):1056-1062
pubmed: 35855346
Clin J Am Soc Nephrol. 2013 Mar;8(3):347-54
pubmed: 23243268
PLoS One. 2020 May 21;15(5):e0232370
pubmed: 32437362
J Clin Oncol. 2006 Aug 20;24(24):4003-10
pubmed: 16921054
Kidney Int Rep. 2021 Jan 28;6(4):1050-1057
pubmed: 33912755
Ecancermedicalscience. 2019 Feb 14;13:903
pubmed: 30915161
Cancer Med. 2019 Jun;8(6):2740-2750
pubmed: 30968593
Oncology. 2011;80(3-4):160-6
pubmed: 21677465
Cancer Manag Res. 2020 Aug 11;12:7199-7207
pubmed: 32848472
Eur J Intern Med. 2011 Aug;22(4):399-406
pubmed: 21767759
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217